A number of research firms have changed their ratings and price targets for Quest Diagnostics (NYSE: DGX):

  • 8/10/2017 – Quest Diagnostics had its price target raised by analysts at Morgan Stanley from $87.00 to $92.00. They now have an “underweight” rating on the stock.
  • 8/9/2017 – Quest Diagnostics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/3/2017 – Quest Diagnostics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Quest Diagnostics’ second-quarter earnings exceeded the Zacks Consensus Estimate, while revenues lagged the same. On a positive note, it has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. It is currently refocusing on core diagnostic information services business and disciplined capital deployment. Finally, the raised 2017 guidance indicates about this bullish trend to continue ahead. In addition, alliance with hospitals and integrated delivery networks are the other growth drivers. Particularly, the company is positive about its acquisition of PeaceHealth in the Pacific Northwest which is expected to bolster growth in the rest 2017. Notably, over the last three months, Quest Diagnostics has been trading above the broader industry. However, we are concerned about tough organic volume scenario. Tough competitive landscape and reimbursement headwinds are other concerns.”
  • 8/2/2017 – Quest Diagnostics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $121.00 price target on the stock. According to Zacks, “Quest Diagnostics’ second-quarter earnings exceeded the Zacks Consensus Estimate, while revenues lagged the same. On a positive note, it has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. It is currently refocusing on core diagnostic information services business and disciplined capital deployment. Finally, the raised 2017 guidance indicates about this bullish trend to continue ahead. In addition, alliance with hospitals and integrated delivery networks are the other growth drivers. Particularly, the company is positive about its acquisition of PeaceHealth in the Pacific Northwest which is expected to bolster growth in the rest 2017. Notably, over the last three months, Quest Diagnostics has been trading above the broader industry. However, we are concerned about tough organic volume scenario. Tough competitive landscape and reimbursement headwinds are other concerns.”
  • 7/28/2017 – Quest Diagnostics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Quest Diagnostics’ second-quarter earnings exceeded the Zacks Consensus Estimate, while revenues lagged the same. On a positive note, it has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. It is currently refocusing on core diagnostic information services business and disciplined capital deployment. Finally, the raised 2017 guidance indicates about this bullish trend to continue ahead. In addition, alliance with hospitals and integrated delivery networks are the other growth drivers. Particularly, the company is positive about its acquisition of PeaceHealth in the Pacific Northwest which is expected to bolster growth in the rest 2017. However, we are concerned about tough organic volume scenario. Tough competitive landscape and reimbursement headwinds are other concerns. Notably, over the last three months, Quest Diagnostics has been trading below the broader industry.”
  • 7/27/2017 – Quest Diagnostics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $123.00 price target on the stock. According to Zacks, “Quest Diagnostics’ second-quarter earnings exceeded the Zacks Consensus Estimate, while revenues lagged the same. On a positive note, it has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. It is currently refocusing on core diagnostic information services business and disciplined capital deployment. Finally, the raised 2017 guidance indicates about this bullish trend to continue ahead. In addition, alliance with hospitals and integrated delivery networks are the other growth drivers. Particularly, the company is positive about its acquisition of PeaceHealth in the Pacific Northwest which is expected to bolster growth in the rest 2017. However, we are concerned about tough organic volume scenario. Tough competitive landscape and reimbursement headwinds are other concerns. Notably, over the last three months, Quest Diagnostics has been trading below the broader industry.”
  • 7/25/2017 – Quest Diagnostics had its price target raised by analysts at Piper Jaffray Companies to $107.00. They now have a “neutral” rating on the stock.
  • 7/25/2017 – Quest Diagnostics was upgraded by analysts at Bank of America Corporation from a “neutral” rating to a “buy” rating. They now have a $118.00 price target on the stock, up previously from $111.00.
  • 7/24/2017 – Quest Diagnostics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/19/2017 – Quest Diagnostics had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $110.00 price target on the stock.
  • 7/16/2017 – Quest Diagnostics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/13/2017 – Quest Diagnostics had its “neutral” rating reaffirmed by analysts at Credit Suisse Group. They now have a $110.00 price target on the stock, up previously from $83.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 7/13/2017 – Quest Diagnostics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Over the last three months, Quest Diagnostics has been trading above the broader industry. We are optimistic about its focus on its recently narrowed two-point strategy. The company has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. In addition, alliance with hospitals and integrated delivery networks are the other growth drivers. Particularly, the company is positive about its agreement with PeaceHealth in the Pacific Northwest, which is expected to bolster growth, later in 2017. Its guidance for 2017 is also encouraging. However, we are concerned about tough organic volume scenario. Tough competitive landscape and reimbursement headwinds are other concerns. Also the stock is currently overvalued as compared to the market and broader industry.”
  • 7/6/2017 – Quest Diagnostics had its price target raised by analysts at UBS Group AG from $115.00 to $123.00. They now have a “buy” rating on the stock.
  • 6/29/2017 – Quest Diagnostics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 6/28/2017 – Quest Diagnostics had its “in-line” rating reaffirmed by analysts at Evercore ISI. They now have a $104.50 price target on the stock.
  • 6/13/2017 – Quest Diagnostics had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $118.00 price target on the stock.

Quest Diagnostics Incorporated (NYSE DGX) opened at 105.61 on Friday. The company has a market capitalization of $14.41 billion, a PE ratio of 21.28 and a beta of 0.69. Quest Diagnostics Incorporated has a 12 month low of $79.12 and a 12 month high of $112.97. The firm’s 50-day moving average is $108.92 and its 200-day moving average is $102.93.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The business had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the previous year, the company posted $1.34 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. Equities analysts anticipate that Quest Diagnostics Incorporated will post $5.70 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, July 24th. Shareholders of record on Monday, July 10th were paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 1.70%. The ex-dividend date was Thursday, July 6th. Quest Diagnostics’s payout ratio is 36.29%.

In other Quest Diagnostics news, SVP Catherine T. Doherty sold 59,762 shares of Quest Diagnostics stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $107.55, for a total value of $6,427,403.10. Following the sale, the senior vice president now owns 78,582 shares of the company’s stock, valued at approximately $8,451,494.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey M. Leiden sold 296 shares of Quest Diagnostics stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $106.66, for a total value of $31,571.36. Following the completion of the sale, the director now directly owns 6,000 shares in the company, valued at approximately $639,960. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,362 shares of company stock worth $6,600,758. Corporate insiders own 1.50% of the company’s stock.

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.